Bone Biologics Corporation
Bone Biologics Corporation (BBLGW) Stock Overview
Explore Bone Biologics Corporation’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
8.2M
P/E Ratio
-1.59
EPS (TTM)
$-0.14
ROE
-2.28%
BBLGW Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Bone Biologics Corporation (BBLGW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.19.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.59 and a market capitalization of 8.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Jeffrey Frelick
2
2 Burlington Woods Drive, Burlington, MA
2021